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Abstract
Chagas disease, caused by the unicellular parasite Trypanosoma cruzi, claims 50,000 lives annually and is the leading cause
of infectious myocarditis in the world. As current antichagastic therapies like nifurtimox and benznidazole are highly toxic,
ineffective at parasite eradication, and subject to increasing resistance, novel therapeutics are urgently needed. Cruzain, the
major cysteine protease of Trypanosoma cruzi, is one attractive drug target. In the current work, molecular dynamics
simulations and a sequence alignment of a non-redundant, unbiased set of peptidase C1 family members are used to
identify uncharacterized cruzain binding sites. The two sites identified may serve as targets for future pharmacological
intervention.
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Introduction
American trypanosomiasis, also known as Chagas disease, is
endemic to Central and South America, where 90 to 100 million
people are at risk of infection [1], 10 to 20 million people are
infected [1,2], and 50,000 die annually [3]. The disease is caused
by the unicellular parasite Trypanosoma cruzi (T. cruzi), an organism
transmitted by insects of the Reduviidae family. After drawing a
blood meal from its human host, the insect reflexively releases
feces containing the parasite into the resulting wound [4]. Once
blood borne, the parasites infiltrate host cells and replicate.
Following replication and maturation, host cells burst open,
releasing new T. cruzi parasites into the bloodstream [5].
The acute phase of the disease, which typically persists for two
months and has a fatality rate of 2 to 8%, is characterized by the
mononuclear inflammation and necrosis of parasitized cells,
especially in the heart [6]. The chronic stage of the disease is
characterized by dilated cardiomyopathy; indeed, American
trypanosomiasis is the leading cause of infectious myocarditis in
the world [7].
New therapies for Chagas disease are urgently needed. Current
treatments, nitrofurans like nifurtimox and benznidazole, are
highly toxic [6,8,9], and drug resistance has been reported [10].
Furthermore, one recent study demonstrated that these com-
pounds neither eradicate the parasite nor prevent cardiomyopathy
over the long term [11].
The major cysteine protease of T. cruzi, called cruzain or,
alternatively, cruzipain, is one attractive drug target [12]. A
member of the peptidase C1 protein family, cruzain is present and
essential in all stages of T. cruzi development [2,13]. Over-
expression of cruzain enhances the transformation of the parasite
into the infective form [14], and reduced protease activity prevents
infection in wild-type mice [9]. Additionally, cysteine protease
inhibitors block both the replication and the differentiation of the
parasite in vitro and in vivo [12,15–22]. Cruzain inhibitors can cure
infection in cell, mouse, and dog models [18,23].
The future rational design of improved cruzain inhibitors
necessitates a better understanding of the flexibility and confor-
mational changes characteristic of the cruzain active site.
Molecular dynamics (MD) simulations, in which the forces that
act on the atoms of a molecular system are approximated using
Newton’s laws of motion, can be powerful tools for better
understanding protein flexibility and conformational sampling
relevant to drug design. For example, one recent MD study of
HIV integrase revealed a previously uncharacterized binding
trench that was subsequently exploited in the design of Isentress
(raltegravir), an HIV drug approved by the FDA in 2007 [24].
Importantly, this trench was not evident in the then available
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MD that the trench was initially identified.
Additional novel sites of enzymatic, allosteric, or structural
importance can be identified computationally by comparing the
sequence of the target protein with evolutionarily related enzymes.
Critical protein residues are often conserved across multiple
members of the same protein family; once multiple sequences are
aligned, conserved patches of protein residues can be easily
identified. Additional experimental studies can then characterize
the pharmacological significance of these patches.
Given the urgent need for novel antichagastic therapeutics, we
here use computational methods, including molecular dynamics
(MD) simulations and a sequence alignment of a non-redundant,
unbiased set of peptidase C1 family members, to identify
previously uncharacterized binding regions that may serve as sites
for future pharmacological intervention.
Methods
MD Simulations
To prepare cruzain for MD simulations, hydrogen atoms were
added to a high-resolution cruzain crystal structure (PDB: 1ME4)
[25] using PDB2PQR to approximate protein protonation at
pH 5.5, the pH of the reservosome where cruzain is located in the
epimastigote stage of the parasite [26–28]. Protonation states were
subsequently verified manually. Hydrogen atoms were added to
the bound hydroxymethyl-ketone inhibitor using Discovery Studio
(Accelrys). The LEaP module of the AMBER9 suite [29] was used
to solvate the system by submerging the protein in a TIP3P water
box [30] that extended 10 A ˚ beyond the protein in all directions.
All crystallographic water molecules were maintained. Ten sodium
cations were added to make the system electrically neutral;
additional ions were then added to simulate a more physiological
20 mM NaCl solution. The system was parameterized using the
generalized and FF99SB AMBER force fields [31,32].
NAMD2.7b1 [33] was used for all MD simulations. Periodic
boundary conditions were employed with the particle mesh Ewald
method to account for electrostatic effects (smoothing cutoff:
14 A ˚). Langevin dynamics were applied to maintain the
temperature, and a modified Langevin piston Nose ´-Hoover
thermostat was used to maintain 1 atm pressure. The initial
structure was minimized in four distinct steps; hydrogen atoms
were first relaxed for 5,000 steps; hydrogen atoms, water
molecules, and ions were next relaxed for 5,000 steps; hydrogen
atoms, water molecules, ions, and protein side chains were then
relaxed for 10,000 steps; and, finally, all atoms were relaxed for
25,000 steps. Following minimization, the system was equilibrated
with an NPT-ensemble at 310 K using stepwise harmonic-
constraint force constants of 4, 3, 2, and 1 kcal/mol/A ˚ 2 on the
protein backbone. 250,000 steps of MD simulation were executed
for each force constant (1 fs time step).
Following minimization and equilibration, five distinct 20-ns
productive runs were performed (10
7 steps of 2 fs) with distinct
random seeds in order to sample many protein configurations.
Trajectory Clustering
The RMSD-based gromos clustering algorithm, as implemented
in the GROMACS++ computer package (g_cluster), was used to
cluster the conformations sampled during the five 20-ns MD
simulations [34]. Structures were first extracted from the
trajectories every 50 fs, generating 4,002 snapshots total. These
snapshots were aligned by their Ca atoms and clustered on the 73
residues of the cruzain active site, defined as all residues within
10 A ˚ of the ligand: 18–31, 50, 53–54, 57–72, 74, 91, 93–98, 115,
117, 120, 136–142, 144–145, 158–165, 181–184, 203–210.
The gromos clustering algorithm was first described by Daura et.
al. [35]. In brief, for each protein conformation in a pool of
conformations, the RMSD distance between the atoms of the
aforementioned residues and the corresponding atoms of every
other protein conformation in the pool (potential ‘‘neighbors’’) is
calculated. The conformation with the most neighbors within a
user-specified distance cutoff (‘‘close neighbors’’) is then selected.
This conformation, together with its close neighbors, constitutes
the first cluster. The protein conformations of the first cluster are
then removed from the pool, and the process is repeated with the
remaining conformations until none are left.
When a cutoff of 0.95 A ˚ was used, this procedure produced 24
clusters. The central member of each cluster was considered most
representative; the set of all central members is said to constitute
an ensemble.
Calculating Beta Factors from the MD Simulation
To derive beta factors from the motions sampled during the
MD simulations, all trajectories were concatenated, and the
RMSF of each protein residue was calculated using the AMBER 9
ptraj module [29]. These RMSF values were converted into beta
factors by multiplication, where b=RMSF * 8p
2/3.
Virtual Screening
A small-molecule library was prepared from the ligands of the
NCI Diversity Set II, a set of freely available, diverse, drug-like
molecules. The Schro ¨dinger LigPrep program (Schro ¨dinger) was
used to assign protonation states at pH 5.5 and to identify and
generate tautomers and stereoisomers. One ligand could not be
processed with LigPrep; instead, hydrogen atoms were added to
this ligand and its geometry was optimized using Discovery Studio
(Accelrys).
The ligands of this small-molecule library were docked into a
1.20 A ˚ cruzain crystal structure (PDB ID: 1ME4; [25]). Hydrogen
atoms were added using PDB2PQR [27,28] at pH 5.5. At this pH,
C25 and H159 formed the thiolate/imidazolium pair required for
the catalytic mechanism [36]. An initial virtual screen was
performed using the CDOCKER docking software (Accelrys)
Author Summary
Chagas disease, an infection that afflicts millions of people
in Central and South America, is caused by the unicellular
parasite Trypanosoma cruzi. In the chronic stage of the
disease, patients’ hearts are adversely affected. Chagas is
the leading cause of infectious heart disease in the world.
The current drugs used to treat Chagas disease are highly
toxic, unable to eradiate the parasite, and subject to
increasing drug resistance. Consequently, researchers are
actively looking for new treatments. One attractive drug
target is a Chagas protein called cruzain, which is required
for the parasite’s survival. Drugs that can inhibit the correct
functioning of cruzain within the parasite may one day
serve as powerful treatments in the fight against this
devastating tropical disease. To design drugs that will be
effective against cruzain, we need to know what portions
of the protein are crucial for its functionality. For example,
portions of the protein that bind to other proteins or to
small molecules are likely to be critical. These regions are
called ‘‘binding sites.’’ In the current work, we identify two
uncharacterized cruzain binding sites. With this knowledge
in hand, future researchers may be able to design drugs
that target these sites.
Uncharacterized Cruzain Binding Sites
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coordinates of the crystallographic ligand, as that program was
able to recapture the crystallographic poses of two known
hydroxymethyl-ketone cruzain inhibitors [25]. The CDOCKER-
predicted pose of each of the ligands was rescored using the PLP2
scoring function [37]. The best ligands as evaluated by PLP2 were
compiled into a new small-molecule ligand library enriched for
potential cruzain inhibitors.
To account for receptor flexibility, we subsequently used the
relaxed-complex scheme [38], a protocol that has been used
previously to identify inhibitors of FKBP [39], HIV integrase [24],
and T. brucei RNA editing ligase 1 [40]. The compounds of the
enriched small-molecule library were docked into the 24 members
of ensemble, again using CDOCKER (Accelrys). Each of these
compounds was rescored with the PLP2 [37] scoring function. For
each ligand, a PLP2-based ensemble-average score was calculated
according to the following equation:
E~
P 23
i~1
wiEi
P 23
i~1
wi
‘ ð1Þ
where E is the weighted ensemble-average score, wi is the size of
cluster i, and Ei is the best score of the ligand, independent of
tautomeric or stereoisomeric form, docked into the centroid of
cluster i.
Alignment of a Non-Redundant, Unbiased Set of
Peptidase C1 Family Members
Cruzain was compared to other members of the peptidase C1
family. First, the UniProt database [41] was used to identify
reviewed members of the peptidase C1 family, as defined by the
MEROPS classification [42], that had structures deposited in the
Protein Data Bank [43]. All amenable sequences except those of
cruzain were then aligned using ClustalW in the MultiSeq
extension of VMD [44–46]. A non-redundant set was selected
from these aligned peptidase C1 sequences (sequence QR: 75; GF:
1.0). Gaps in the sequences were then removed, and ClustalW was
used to align the corresponding sequences to a cruzain crystal
structure (PDB: 1AIM) that was chosen as a non-redundant
structure from the set of all cruzain structures aligned using
STAMP [47]. The following sequences were aligned: 1A6R,
1AEC, 1CJL, 1DEU, 1FWO, 1JQP, 1K3B, 1M6D, 1PCI, 1XKG,
2C0Y, 2CB5, 2FO5, 2O6X, 2WBF, 3PBH, 7PCK, and 8PCH.
Residues were colored by similarity according to the BLOS-
SUM30 matrix.
Results and Discussion
Motivated by the urgent need for novel antichagastic therapeu-
tics, we set out to identify previously uncharacterized cruzain sites
that might serve as future targets for pharmacological intervention.
Five 20-ns MD simulations were first used to probe the dynamics
of the cruzain active site, as knowledge of protein dynamics can
provide important structural insights beyond the information that
can be obtained from crystal structures alone.
System Equilibration
While four of the five 20-ns MD simulations equilibrated, as
judged by convergent RMSD values, the RMSD plot of the first
simulation suggested that several conformational states had been
sampled (Figure 1). A careful examination of the trajectory
revealed that a mobile N-terminal tail was entirely responsible for
the non-convergent RMSD values of the first simulation. In the
crystal structure (PDB: 1ME4) [25], as in four of the five MD
simulations, the N-terminal tail is held against the protein via
hydrogen bonds between the A3 backbone carbonyl and the D167
backbone amine, and between the P2 backbone carbonyl and the
Y166 side-chain hydroxyl group. In the first MD simulation,
however, the hydrogen bond between P2 and Y166 broke after
6.7 ns. After 14.3 ns, the bond between A3 and D167 broke,
allowing the N-terminal tail to rotate such that new hydrogen
bonds were formed between the D167 side-chain carboxylate
group and the backbone amines of both A3 and A4. After 18.7 ns,
the N-terminal tail returned to its original position. While these
conformational changes are interesting, they occur far from the
peptide binding site and so are probably not relevant to drug
design. Importantly, when the first three residues of the protein are
omitted from the RMSD calculation, the RMSD plot of the first
MD simulation is convergent, similar to the RMSD plots of the
other four simulations.
The Cruzain Active Site
The MD simulations were subsequently used to study the
flexibility of the cruzain active site. Cruzain, like other cysteine
proteases, contains seven subsites that bind peptide amino acids.
Four subsites on the acyl side of the cleaved peptide bond, named
S4, S3, S2, and S1, bind the peptide amino acids P4, P3, P2, and
P1. Three subsites on the amino side of the bond, named S19,S 2 9,
S39, bind the peptide amino acids P19,P 2 9, and P39 (Figure 2)
[48]. The only well defined subsites of these seven are S2, S1,
and S19, and only S2 and S19 demonstrate significant specificity
[49].
To judge the flexibility of the cruzain active site, the beta factor
of each protein residue was calculated from the molecular motions
sampled during the MD simulation. In general, the active site was
remarkable for its great stability, likely in part due to the bound
hydroxymethyl-ketone inhibitor [25].
Figure 1. MD equilibration. The five MD trajectories were aligned by
protein alpha-carbon atoms, and the RMSD of each trajectory relative to
the first frame was calculated as a function of time. The protein N-
terminal tail of the first simulation assumed several rotameric states.
The remaining four simulations were equilibrated, as demonstrated by
their convergent RMSD values.
doi:10.1371/journal.pntd.0000676.g001
Uncharacterized Cruzain Binding Sites
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To better distinguish between the many conformational states
sampled by the MD simulations, 4,002 protein configurations were
extracted from the simulations at regularly spaced intervals and
grouped into 24 clusters by RMSD using the gromos clustering
algorithm [35]. The centroid member was selected from each
cluster, and the set of all centroid members, representative of the
many conformations sampled by the MD simulations, is said to
constitute an ensemble.
Virtual Screening
To test the potential physiological relevance of the ensemble-
member active-site conformations, CDOCKER (Accelrys) was
used to dock the compounds of the NCI Diversity set II, a set of
freely available, diverse, drug-like molecules, into both the
cruzain crystal structure and the 24 protein conformations of
the ensemble. A full account of the results of this virtual screen
is forthcoming; however, one of the predicted inhibitors
warrants further discussion here. Compound 1 (clorobiocin,
Figure 3) was the best predicted novel cruzain inhibitor as
evaluated by the PLP2 scoring function [37] in both the screen
against the static crystal structure and the relaxed-complex
screen against the ensemble of 24 conformations. As positive
controls, two hydroxymethyl-ketone inhibitors (PDB: 1ME3)
[25] were included in the relaxed-complex screen. After
rescoring with an ensemble-average PLP2 score, these com-
pounds ranked even better than compound 1,c o n f i r m i n gt h a t
the PLP2 scoring function is well suited to this particular
protein receptor.
We note with interest that previous studies have demonstrated
that compound 1 antagonizes T. cruzi amastigote growth [50,51].
The primary protein target of clorobiocin is thought to be T. brucei
topoisomerase II, but the idea of a polypharmacophoric
mechanism that includes cruzain inhibition is interesting. The
PLP2 scores of compound 1 docked into the central members of
the first, second, and third most populated clusters were 95.07,
117.7, and 115.68, respectively.
To understand why compound 1 binding to the second
ensemble conformation was favored, the pose of the ligand docked
into that conformation was analyzed. While docking poses should
never be blindly accepted, this particular pose seemed promising.
Aside from having the best PLP2 score, this binding mode placed a
conjugated ring in the S2 pocket, similar to the binding modes of
some known ligands (e.g. some vinyl sulfone inhibitors [52]) and of
some native substrates [53]. Importantly, the docked pose also
suggested that one of the ligand rings binds in a previously
uncharacterized, druggable pocket immediately beyond the S2
subsite (Figure 3).
Figure 2. The cruzain active site colored according to the seven substrate-binding subsites. Four subsites on the acyl side of the cleaved
peptide bond, named S4, S3, S2, and S1, bind the peptide amino acids P4, P3, P2, and P1. Three subsites on the amino side of the bond, named S19,
S29,S 3 9, bind the peptide amino acids P19,P 2 9, and P39. As no crystal structure of cruzain bound to a peptide substrate was available, the peptide
shown was taken from a crystal structure of the homologous protein procathepsin K (PDB: 1BY8).
doi:10.1371/journal.pntd.0000676.g002
Uncharacterized Cruzain Binding Sites
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The beta factors of the protein residues that from this previously
uncharacterized pocket revealed significant protein flexibility. Two
of the residues that form the distal wall of the S2 subsite, L67 and
E205, were somewhat flexible (Figure 4D), and two other protein
residues beyond the S2 subsite, N69 and E112, were also mobile
(Figure 4D). Together, these four flexible residues comprise two
‘‘gates’’ (L67-E205 and N69-E112) that, when open, form the
walls of a previously uncharacterized druggable pocket that
medicinal chemists have yet to exploit.
Published cruzain crystal structures hint at the existence of this
additional pocket. A crystal structure of cruzain bound to a vinyl
sulfone derived inhibitor (PDB: 2EFM) demonstrates a closed
configuration (Figure 4B), while a crystal structure of cruzain
bound to a hydroxymethyl-ketone inhibitor (PDB: 1ME3) [25]
demonstrates a semi-open configuration (Figure 4F).
The crystal structures, however, do not fully capture the extent
of opening demonstrated by the MD simulations. The central
member of the top cluster, which accounted for 82.5% of the
trajectory, had a closed conformation (Figure 4A). The central
member of the second cluster, accounting for 6.9% of the
trajectory, had a semi-open conformation (Figure 4C), and the
central member of the third cluster, accounting for 3.6% of the
trajectory, was fully open (Figure 4E). As shown in Figures 4C and
4E, molecular docking demonstrates that both the semi-open and
the fully open conformations can easily accommodate small
molecular fragments.
The First Gate
To further characterize the opening and closing of the first gate,
the distance between the L67 c carbon atom and the E205 d
carbon atom (d1) was monitored over all 100 ns of trajectory. A
histogram of these distances was bimodal (Figure 5A) and
suggested that the gate was open (d1.6.25 A ˚) 70% of the time
(d1=7.6 A ˚60.6) and closed (d1,6.25 A ˚) 30% of the time
(d1=5.4 A ˚60.4). As a reference, this same distance is 7.8 A ˚ and
8.4 A ˚ in the semi-open and fully open conformations, respectively,
both of which can accommodate a ligand (Figures 4C and 4E).
We note that the presence of the hydroxymethyl-ketone
inhibitor may have affected the dynamics of the first gate by
largely immobilizing the E205 residue in an open conformation.
E205 plays a unique role in substrate binding. The cruzain S2
subsite, like that of cathepsin B, differs from other cysteine
proteases in that it can bind both hydrophobic and basic amino
acids [2,53]. The E205 residue acts as a highly mobile switch.
When a basic amino acid like arginine occupies the S2 subsite, the
acidic E205 carboxylate group swings into S2 to interact with the
guanidino group, a conformation that can be seen in the crystal
structure of cruzain bound to benzoyl-arginine-alanine-methyl
ketone (PDB: 2AIM) [2,53]. When a hydrophobic amino acid
occupies the S2 subsite, E205 rotates away from S2 and interacts
with the solvent [2,53], a conformation evident in the crystal
structure of cruzain bound to WRR-99 (PDB: 1EWL).
The hydrophobic phenyl group of the hydroxymethyl-ketone
inhibitor present in the S2 subsite of the MD simulation locked
E205 in the open, solvent exposed conformation (Figure 4D).
Consequently, the dynamics of the first gate were mostly
determined by L67. A histogram of the dihedral angle defined
by the backbone amino nitrogen atom and the a, b, and c carbon
atoms of L67, measured over the course of the trajectory,
demonstrated that the side chain of this important residue rotated
freely (Figure 5B). Visual inspection confirmed that gate opening
occurred when the dihedral angle (h1) was roughly 260u
(d1=7.6 A ˚60.7 when 2140u,h1,60u), and that gate closing
occurred when the dihedral angle was roughly 180u
(d1=5.7 A ˚60.7 when h1,2140u or h1.60u). By this metric, the
first gate was open 67% of the time, a value that matches that
found by measuring the distance between the L67 c carbon atom
and the E205 d carbon atom directly.
The Second Gate
To assess the opening and closing of the second gate, the
distance between the N69 side-chain amino nitrogen atom and the
E112 d carbon atom (d2) was monitored over all 100 ns of
trajectory. A histogram of these distances was again bimodal
(Figure 5A) and suggested that the second gate is open (d2.4.5 A ˚)
43% of the time (d2=6.0 A ˚61.1), and closed (d2,4.5 A ˚) 57% of
the time (d2=3.7 A ˚60.4). As a reference, this same distance is
5.3 A ˚ in the fully open conformation, which can accommodate a
ligand (Figure 4E).
Both N69 and E112, which form the second gate, are mobile.
Of these two residues, E112 is particularly flexible (Figure 4D).
Visual inspection of the trajectory confirmed that N69 and E112
interact with each other via a transient hydrogen bond between the
N69 side-chain amino nitrogen atom and the E112 carboxylate
oxygen atoms (Figure 5C). A hydrogen bond between these two
residues (distance cutoff of 3.5 A ˚) was present in roughly 30% of
the frames extracted from the trajectory.
Figure 3. The binding of compound 1 to the semi-open
conformation of cruzain. Compound 1 (clorobiocin, bottom), a
known antagonist of T. cruzi amastigote growth, is predicted to occupy
a previously uncharacterized binding pocket adjacent to the S2 subsite
(top).
doi:10.1371/journal.pntd.0000676.g003
Uncharacterized Cruzain Binding Sites
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the solvent, where the carboxylate group interacted with water
molecules. A histogram of the dihedral angle defined by the
backbone amino nitrogen atom and the a, b, and c carbon atoms
of E112 (h2), measured over the course of the trajectory, confirmed
that the side chain of this important residue can freely rotate
(Figure 5B). Visual inspection demonstrated that gate opening
occurred at two rotameric states, when the dihedral angle was 60u
or 180u (d2=5.9 A ˚61.4 when h2.0u or h2,2140u). Gate closing
occurred when the dihedral angle was 260u (d2=4.1 A ˚60.9 when
2140u,h2,0u). By this metric, the second gate was open 34% of
the time.
Types of Fragments That Bind This Previously
Uncharacterized Pocket
To determine what kinds of molecular fragments would best fit
into the previously uncharacterized pocket immediately beyond
the S2 subsite, we examined the predicted binding poses of NCI
compounds docked into the third (fully open) ensemble confor-
mation (Figure 4E). Roughly two-dozen ligands were predicted to
occupy the previously uncharacterized pocket and to bind cruzain
with high affinity. With some exceptions, the molecular fragments
occupying the previously uncharacterized pocket were generally
aromatic rings or aliphatic chains, often with hydroxyl groups that
formed hydrogen bonds with the E205 carboxylate oxygen atoms.
Numerous FDA-approved drugs contain hydroxylated rings (e.g.
masoprocol, carbidopa, acetaminophen, etc.) and/or aliphatic
chains (e.g. penciclovir, ethambutol, and miglitol), and so these
fragments can be considered drug like.
Alignment of a Non-Redundant, Unbiased Set of
Peptidase C1 Family Members
Having used MD simulations to identify a previously unchar-
acterized binding pocket immediately beyond the S2 subsite, we
next used a bioinformatics approach to identify other possible sites
of importance. Residues critical to protein function, like those of
an enzymatic or allosteric active site, like those that participate in
essential protein-protein interactions, or like those that play
important structural roles, are often conserved across multiple
homologous members of the same protein family. To identify these
critical residues, cruzain was compared to other members of the
peptidase C1 family.
As expected, the residues of the seven subsites of the proteolytic
binding pocket are generally conserved (Figure 6A, S1). The S2
subsite, critical for specificity, is an important exception; this site,
like the S2 subsite of cathepsin B, differs from other cysteine
proteases in that it can bind both hydrophobic and basic amino
acids [2,53].
Additionally, the six cysteine residues involved in disulfide
bonds are conserved, suggesting that these bonds are critical for
protein tertiary structure. A natural mutation in human cathepsin
C, a related cysteine protease with the same papain fold, confirms
this importance. Patients with a cathepsin C C291Y mutation,
equivalent to a cruzain C56Y mutation, develop Papillon-Lefe `vre
syndrome due to cathepsin C dysfunction [54].
Surprisingly, there are two patches of highly conserved residues
on the side of the protein opposite the proteolytic active site. The
first, patch one, is comprised of Y88, P87, E83, Y86, Q51, and
S49. The second, patch two, is comprised of Y186, R8, V16, G11,
D6, and V13 (Figure 6B, S1). Both of these patches lie in a long
shallow groove, formed largely by several disordered loops, which
traverses the protein surface (Figure 6B). These loops include the
loops spanning G11 to G23 (loop11–23), G42 to S48 (loop42–48),
Y86 to T101 (loop86–101), and N175 to G185 (loop175–185).
Though disordered, these loops are held rigid by the conserved
residues of the two patches, which bind the loops to stable tertiary
structures and/or to each other. This rigidity may serve to
maintain the shape of the traversing groove.
To the best of our knowledge, this groove and its associated
conserved patches, which are common to members of the
peptidase C1 family, have not been previously characterized.
These highly conserved patches may play roles in allosteric
regulation or structural stability. Additionally, the shallow
traversing groove formed by these two patches may also constitute
a surface amenable to protein binding.
We first turned our attention to the first patch of conserved
residues. S49 and Q51 are highly conserved buried residues that
belong to a stable helix spanning S49 to L56 (helix49–56).
Interactions between these residues and residues of loop86–101
help to pin the loop against the stable helix, thereby imparting
stability to part of the traversing groove. The S49 side-chain
hydroxyl group hydrogen bonds with the backbone carbonyl
oxygen of Y86, another conserved residue. Additionally, the side-
chain carbonyl oxygen atom of Q51 forms two hydrogen bonds,
one with the backbone amine of A89 and one with the side-chain
hydroxyl group of S89. The side-chain amine of Q51 hydrogen
also hydrogen bonds with the side-chain hydroxyl group of S89
(Figure 6C).
Though cruzain mutagenesis data is absent from the literature,
studies of the closely related human cathepsin C protein likewise
suggest that S49 and Q51 have important roles. Patients with a
cathepsin C S284N mutation, analogous to a cruzain S49N
mutation, develop Papillon-Lefe `vre syndrome [55], and patients
with a cathepsin C Q286R mutation, analogous to a cruzain
Q51R mutation, develop Haim-Munk syndrome. Both these
syndromes are caused by cathepsin C dysfunction [56].
Y86 and P87, also conserved residues of the first patch, likewise
seem to play an important role in imparting rigidity to the
disordered loop86–101. The Y86 side-chain hydroxyl group forms
two hydrogen bonds with T96, helping to maintain the hairpin
shape of loop86–101. P87 does not participate in any hydrogen
bonds, but the conformational rigidity of the proline backbone
may contribute to the overall rigidity of loop86–101 as well
(Figure 6C).
The rigidity of loop86–101 is in part transferred to loop11–23 and
loop42–48 via the conserved residues Y88 and E83, respectively.
The Y88 side-chain hydroxyl group hydrogen bonds with the Q19
Figure 4. A previously uncharacterized binding pocket adjacent to the S2 subsite. The protein conformations depicted in A, B, C, E, and F
are shown from the same orientation. Molecular fragments were excised from selected members of the NCI diversity set docked into semi-open and
fully open protein conformations extracted from the MD simulation. A) The central member of the first cluster extracted from the MD simulation, in
which the pocket is closed. The S2 subsite, as well as the first and second gate, are labeled. B) A cruzain crystal structure (PDB: 2EFM) in which the
pocket is likewise closed. C) The central member of the second cluster, in which the pocket is semi-open. A small molecular fragment is shown
docked into the pocket to demonstrate druggability. D) The cruzain active site with residues colored according to beta values calculated from the MD
simulation. Blue indicates stability, and red indicates mobility. Several of the residues that comprise the previously uncharacterized pocket are
flexible. E) The central member of the third cluster, in which the pocket is fully open. A small molecular fragment is shown docked into the pocket to
demonstrate druggability. F) A cruzain crystal structure (PDB: 1ME3) in which the pocket is semi-open.
doi:10.1371/journal.pntd.0000676.g004
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hydrogen bonds with the N47 backbone carbonyl oxygen atom,
thereby holding all these loops rigid relative to one another. It is
also interesting to note that the side-chain carboxylate group of
N47 is solvent exposed and potentially capable of interacting with
other proteins or small-molecule compounds that may bind in the
traversing groove (Figure 6C).
We next turned our attention to the second patch of conserved
residues. The conserved residues of this patch likewise serve to
hold disordered loops rigid against underlying secondary struc-
tures. For example, a hydrogen bond exists between the backbones
of two highly conserved residues, G11 and R8, that anchors part of
loop11–23 to a small helix spanning W7 to R10 (helix7–10). Helix7–
10 is in turn positioned relative to an underlying beta sheet by
multiple hydrogen-bond interactions between the conserved
residues R8 and D6. These interactions are likely critical for
protein function; D6 is analogous to the cathepsin C residue D236,
and patients with D236Y mutations develop Papillon-Lefe `vre
syndrome, again suggesting cathepsin C dysfunction (Figure 6D)
[54].
Figure 5. The opening and closing of the two ‘‘gates’’ that comprise the previously uncharacterized pocket. A) Histograms of the
distances between the L67 c carbon atom and the E205 d carbon atom (the first gate, in black), and the distances between the N69 side-chain amino
nitrogen atom and the E112 d carbon atom (the second gate, in gray), over all 100 ns of trajectory. When the L67-E205 distance is ,7.5 A ˚, the first
gate is open. When ,5.5 A ˚, the gate is closed. Similarly, when the N69-E112 distance is ,6.0 A ˚, the second gate is open; when ,3.5 A ˚, the gate is
closed. B) Histograms of the dihedral angles defined by the backbone amino nitrogen atom and the a, b, and c carbon atoms of L67 (in gray) and
E112 (in black), respectively, measured over the course of the trajectory. The first gate is open when the L67 dihedral angle is ,60u and closed when
,180u. The second gate is open when the E112 dihedral angle is 60u or 180u, and closed when 260u. C) A histogram of the distances between the
N69 side-chain amino nitrogen atom and the E112 carboxylate oxygen atoms, demonstrating the formation of a transient hydrogen bond.
doi:10.1371/journal.pntd.0000676.g005
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structure and rigidity to loop175–185. The backbone of the
conserved residue Y186, part of a stable underlying beta sheet,
forms two hydrogen bonds with the backbone of E183. These
interactions not only hold part of loop175–185 fixed relative to the
beta sheet, but also help stabilize a sharp turn at the sheet-loop
junction. Additionally, the phenol group of Y186 forms an
interesting p-cation interaction with R8, also conserved. This
Figure 6. Cruzain (PDB: 1AIM) colored by residue conservation across multiple members of the peptidase C1 family. Conserved
residues are shown in blue, and nonconserved residues are shown in red. A) The residues of the seven peptide-binding subsites are generally
conserved. The S2 subsite, critical for specificity, is an important exception. Additionally, one of the residues of the previously uncharacterized
binding pocket immediately beyond the S2 subsite, L67, is well conserved, while the remaining three residues of the pocket, N69, E112, and E205, are
not. B) Two patches of highly conserved residues on the side of the protein opposite the proteolytic active site can be seen. The first, patch one, is
comprised of Y88, P87, E83, Y86, Q51, and S49. The second, patch two, is comprised of Y186, R8, V16, G11, D6, and V13. C) A close-up view of the first
patch. Conserved residues are shown in licorice, and non-conserved residues are shown in balls and sticks. Side chains or backbone atoms that do not
participate in hydrogen bonds have been removed for the sake of clarity. D) A similar close-up view of the second conserved patch.
doi:10.1371/journal.pntd.0000676.g006
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sheet, contributing to the overall curvature of the traversing
groove (Figure 6D).
Two additional conserved residues of the second patch, V13
and V16, do not participate in any hydrogen-bond interactions
and have no obvious structural importance. Nevertheless, V16
likely has a critical, albeit unknown, role in protein function. V16
is analogous to the cathepsin C residue V249. Patients with V249F
mutations develop Papillon-Lefe `vre syndrome, again suggesting
cathepsin C dysfunction [57]. Clearly, additional research is
needed to further characterize these conserved patches and the
traversing groove in which they are located (Figure 6D).
If we accept the hypothesis that in vivo the traversing groove
constitutes a surface positioned at an important protein-protein
interface, small molecules that target specific residues critical for
protein binding may be able to disrupt the protein-protein
interaction and potentially inhibit cruzain function. We note,
however, that many of the residues that form the traversing groove
are homologous with residues of human cathepsin C, and so
relevant cruzain inhibitors are likely to inhibit cathepsin C as well.
However, several residues, located between the two conserved
patches (Figure 6B), are not themselves conserved. For example,
the cathepsin C residues homologous to cruzain A15 and N47 are
I258 and P224, respectively. It may therefore be possible to design
cruzain-specific inhibitors that bind to non-conserved residues like
A15 and N47.
Conclusion
Chagas disease, caused by the unicellular parasite T. cruzi,
claims 50,000 lives annually [3] and is the leading cause of
infectious myocarditis in the world [7]. As current antichagastic
therapies like nifurtimox and benznidazole are highly toxic [6,8,9],
ineffective at parasite eradication [11], and subject to increasing
resistance [10], novel therapeutics are urgently needed.
Cruzain, the major cysteine protease of T. cruzi, is one attractive
drug target [12]. In order to further the development of cruzain
inhibitors, we here used MD simulations to identify a previously
uncharacterized druggable pocket adjacent to the S2 subsite and a
sequence alignment of a non-redundant, unbiased set of peptidase
C1 family members to identify two conserved patches that may
play roles in allosteric regulation, structural stability, or protein-
protein interactions.
Future directions include using computer-aided drug design to
identify and characterize cruzain inhibitors that exploit the
previously uncharacterized pocket immediately beyond the S2
subsite. Considerably more effort is required to characterize and
exploit the two conserved patches opposite the peptide-binding
site. While several of the residues of these patches are known to be
critical for the function of cathepsin C, a cruzain homologue,
mutagenesis studies are needed to directly confirm that they play
an essential role in cruzain function as well. Once established as
important, experiments are needed to further characterize the role
these patches play. Two-hybrid screening or co-immunoprecipi-
tation may identify other T. cruzi proteins that interact with
cruzain. X-ray crystallography could then be used to determine
whether or not these protein partners bind to the traversing groove
formed by the two conserved patches identified in the current
study. Additionally, small-molecule compounds that bind these
patches may be useful tools for probing possible allosteric effects
and/or disrupting critical protein-protein interactions.
Supporting Information
Figure S1 The alignment of selected peptidase C1 family
members.
Found at: doi:10.1371/journal.pntd.0000676.s001 (0.18 MB PDF)
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